Population pharmacokinetics in veterinary medicine: Potential use for therapeutic drug monitoring and prediction of tissue residues

Journal of Veterinary Pharmacology and Therapeutics

Volumn 21, Issue 3, 1998, Pages 167-189

  Martin Jimenez T ^a   Riviere, J E ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOSE RESPONSE; DRUG DISPOSITION; DRUG LABELING; DRUG MONITORING; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG UTILIZATION; PREDICTION; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; STATISTICAL ANALYSIS; TISSUE DISTRIBUTION; VETERINARY MEDICINE;

ANIMALS; DAIRY PRODUCTS; DRUG DESIGN; DRUG MONITORING; DRUG RESIDUES; EGGS; MEAT; MODELS, STATISTICAL; STATISTICS, NONPARAMETRIC; TISSUE DISTRIBUTION; VETERINARY DRUGS;

EID: 0031745930     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2885.1998.00121.x     Document Type: Review

References (64)

1. Aarons, L., Vozeh, S., Wenk, M. & Weiss, Ph. & Follath, R. (1989) Population pharmacokinetics of tobramycin. British Journal of Clinical Pharmacology, 28, 305-314.
2. Al-Banna, M.K., Kelman, A.W. & Whiting, B. (1990) Experimental design and efficient parameter estimation in population pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics, 18, 347-359.
3. Anon (1997) Guidance for industry. Population Pharmacokinetics Draft Guidance. Food and Drug Administration Center for Drug Evaluation and Research.
4. Beal, S.L. (1984a) Population Pharmacokinetic data and parameter estimation based on their first two statistical moments. Drug Metabolism Reviews, 15, 173-193.
5. Beal, S.L. (1984b) Asymptotic properties of optimization estimators for the independent not identically distributed case with application to extended least squares estimators. Technical Report of the Division of Clinical Pharmacology, University of California, San Francisco, 1984.
6. Beal, S.L. & Sheiner, L.B. (1980) The NONMEM system. American Statistician, 34, 118-119.
7. Beal, S.L. & Sheiner, L.B. (1989) NONMEM Users Guide. Part 1: Users Basic Guide, Technical Report of the Division of Clinical Pharmacology, University of California, San Francisco.
8. Boeckmann, A.J., Sheiner, L.B. & Beal, S.L. (1994) NONMEM Users Guide. Part V: Introductory Guide, Technical Report of the Division of Clinical Pharmacology, University of California, San Francisco.
9. Bruno, R., Vivier, N., Vergniol, J.C., De Phillips, S.L., Montay, G. & Sheiner, L.B. (1996) A Population Pharmacokinetic Model of Doxetacel (Taxotere 7): Model Building and Validation. Journal of Pharmacokinetics and Biopharmaceutics, 24, 153-172.
10. Cosson, V., Fuseau, E., Efthymiopoulos, C. & Bye, A. (1995) From animal to man. Proceedings of the 3rd Population Approach Group in Europe Meeting. Frankfurt, Germany.
11. D'Argenio, D.Z. (1981) Optimal sampling times for pharmacokinetic experiments. Journal of Pharmacokinetics and Biopharmaceutics, 9, 739-756.
12. D'Argenio, D.Z. & Schumitzky, A. (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Computer Programs in Biomedicine, 9, 115-134.
13. D'Argenio, D.Z. & Schumitzky, A. (1997) ADAPT II User's Guide. Biochemical simulations resource. University of Southern California. Los Angeles, CA.
14. Davidian, M. & Gallant, A.R. (1992a) The nonlinear mixed effects model with a smooth random effects density. Institute of Statistics Mimeo Series no. 2206. North Carolina State University, Raleigh.
15. Davidian, M. & Gallant, A.R. (1992b) Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine. Journal of Pharmacokinetics and Biopharmaceutics, 20, 529-561.
16. Dodge, W.F., Jelliffe, R.W., Richardson, C.J., McCleery, R.A., Hokanson, J.A. & Snodgrass, W.R. (1991) Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method. Clinical Pharmacology and Therapeutics, 50, 25-31.
17. Efron, B. (1983) Estimating the error rate of a prediction rule: improvement on Cross-validation. Journal of the American Statistical Association, 78, 316-331.
18. Ette, E.I. (1997) Population model stability and performance. Journal of Clinical Pharmacology, 37, 486-495.
19. Ette, E.I., Kelman, A.W., Howie, C.A. & Whiting, B. (1995a) Analysis of animal pharmacokinetic data: performance of the one point per animal design. Journal of Pharmacokinetics and Biopharmaceutics, 23, 551-566.
20. Ette, E.I. & Ludden, T.M. (1995b) Population pharmacokinetic modeling: The importance of informative graphics. Pharmaceutical Research, 12, 1845-1855.
21. Fattinger, K., Vozeh, S., Olafsson, A., Vlcek, J., Wenk, M. & Follath, F. (1991) Netilmicin in the neonate: Population pharmacokinetic analysis and dosing recommendations. Clinical Pharmacology and Therapeutics, 50, 55-65.
22. Forrest, A., Ballow, C.H., Nix, D. & Schentag, J.J. (1991a) A new approach for designing population sparse sampling strategies-applied to ciprofloxacin pharmacokinetics. Clinical Pharmacology and Therapeutics, 49, 153.
23. Forrest, A., Hawtoff, J. & Egorin, M.J. (1991b) Evaluation of a new program for population PK/PD analysis: applied to simulated phase I data. Clinical Pharmacology and Therapeutics, 49, 153.
24. Gilman, T.M., Brunnemann, S.R. & Segal, J.L. (1993) Comparison of population pharmacokinetic models for gentamicin in spinal cord-injured and able-bodied patients. Antimicrobial Agents and Chemotherapy, 37, 93-98.
25. Grasela, T.H. & Sheiner, L.B. (1991) Pharmacostatistical modeling for observational data. Journal of Pharmacokinetics and Biopharmaceutics, 19, 25S-36S.
26. Higuchi, S., Yukawa, E. & Aoyama, T. (1988) Bayesian prediction of serum phenytoin concentration in a simulation study. Chemical Pharmaceutical Bulletin, 36, 1914-1918.
27. Hurst, A., Yoshinaga, M., Mitani, G., Foo, K., Jelliffe, R. & Harrison, E. (1990) Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrobial Agents and Chemotherapy, 34, 1165-1171.
28. Jelliffe, R., Iglesias, T., Hurst, A., Foo, K. & Rodriguez, J. (1991) Individualizing gentamicin dosage regimens: a comparative review of selected models, data fitting methods, and monitoring strategies. Clinical Pharmacokinetics, 22, 461-478.
29. Jelliffe, R.W., Maire, P., Sattler, F., Gomis, C. & Tahani, B. (1994) Adaptive control of drug dosage regimens: basic foundations, relevant issues, and clinical examples. International Journal of Bio-Medical Computing, 36, 1-23.
30. Jelliffe, R.W., Schumitzky, A. & Van Guilder, M. (1995) User Manual for Version 10.6 of the USC*PACK Collection of PC Programs. Laboratory for Applied Pharmacokinetics, USC School of Medicine, Los Angeles, CA.
31. Jelliffe, R.W., Schumitzky, A., Van Guilder, M., Liu, M., Hu, L., Maire, P., Gomis, P., Barbaut, X. & Tahani, B. (1995) Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models. Bayesian fitting and adaptive control. Therapeutic Drug Monitoring, 15, 380-393.
32. Jennrich, R. & Sampson, P. (1976) Newton-Raphson and related algorithms for maximum likelihood variance component estimation. Technometrics, 18, 11-15.
33. Kataria, B.K., Ved, S.A., Nicodemus, H.F., Hoy, G.R., Lea, D., Dubois, M.Y., Mandema, J.W. & Shafer, S.L. (1994) The pharmacokinetics of propofol in children using three different data analysis approaches. Anesthesiology, 80, 104-122.
34. Kisor, D.F., Watling, S.M., Zarowitz, B.J. & Jelliffe, R.W. (1992) Population pharmacokinetics of gentamicin. Use of the nonparametric expectation maximization (NPEM) algorithm. Clinical Pharmacokinetics, 23, 62-68.
35. Lee, T.C., Charles, B., Steer, P., Flenady, V. & Shearman, A. (1997) Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clinical Pharmacology and Therapeutics, 61, 628-640.
36. Maitre, P.O., Auseums, M.E., Vozeh, S. & Stanski, D.R. (1988) Evaluating the accuracy of using population pharmacokinetic data to predict plasma concentrations of allentanil. Anesthesiology, 68, 59-67.
37. Mallet, A. (1986) A maximum likelihood estimation method for random coefficient regression models. Biometrika, 73, 645-656.
38. Mallet, A., Mentre, F., Steimer, J.L. & Lokiec, F. (1988) Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine. Journal of Pharmacokinetics and Biopharmaceutics, 16, 311-327.
39. Martinez, M.N., Riviere, J.E. & Koritz, G.D. (1995) Review of the first interactive workshop on professional flexible labeling. Journal of the American Veterinary Medical Association. 207, 865-914.
40. Martín-Jiménez, T., Papich, M. & Riviere, J.E. (1998) Population pharmacokinetics of gentamicin in horses. American Journal of Veterinary Research, (in press).
41. Peck, C.C., Barr, W.H. & Benet, L.Z. (1992) Opportunities for integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development. Clinical Pharmacology and Therapeutics, 51, 465-473.
42. Prévost, G. (1977) Estimation of a normal probability density function from samples measured with nonnegligible and nonconstant dispersion. Internal Report. Adersa-Gerbios, Palaiseau, France.
43. Rao, C.R. (1965) Linear statistical inference and its applications. John Wiley & Sons, Inc., New York.
44. Riviere, J.E. (1984) The value and limitation of pharmacokinetics in predicting dosage regimens: effects of systemic disease. Proceedings of symposium on dose determination with animal drugs. Ohio State University Press, Columbus, OH.
45. Riviere, J.E. (1988) Veterinary clinical pharmacokinetics. Part II: Modeling. Compendium Continuing Education Practicing Veterinarian, 10, 313-328.
46. Riviere, J.E., Martín-Jiménez, T., Sundlof, S.F. & Craigmill, A.L. (1997) Interspecies allometric analysis of the comparative pharmacokinetics of 44 drugs across veterinary and laboratory animal species. Journal of Veterinary Pharmacology and Therapeutics, 20, 453-463.
47. Roecker, E.B. (1991) Prediction error and its estimation for subset-selected models. Technometrics, 33, 459-468.
48. Schmitz, V.O., Fiedler-Kelly, J., Phillips, L. & Grasela, T.H. (1997) Prospective use of population pharmacokinetics/pharmacodynamics in the development of cisatracurium. Pharmaceutical Research, 14, 91-97.
49. Schumitzky, A. (1991) Nonparametric EM algorithms for estimating prior distributions. Applied Mathematics and Computation, 45, 141-157.
50. Sheiner, L.B. (1992) Population approach in drug development: rationale and basic concepts. In New strategies in drug development and clinical evaluation: the population approach. Eds Rowland M. & Aarons L. pp. 13-29. Commission of the European Communities, Luxembourg.
51. Sheiner, L.B. (1994) A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clinical Pharmacology and Therapeutics, 56, 509-522.
52. Sheiner, L.B. & Beal, S.L. (1980) Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. Journal of Pharmacokinetics and Biopharmaceutics, 8, 553-571.
53. Sheiner, L.B. & Beal, S.L. (1981a) Some suggestions for measuring predictive performance. Journal of Pharmacokinetics and Biopharmaceutics, 9, 503-512.
54. Sheiner, L.B. & Beal, S.L. (1981b) Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model; experimental pharmacokinetic data. Journal of Pharmacokinetics and Biopharmaceutics, 9, 635-651.
55. Sheiner, L.B. & Beal, S.L. (1983) Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model; routine clinical pharmacokinetic data. Journal of Pharmacokinetics and Biopharmaceutics, 11, 303-319.
56. Sheiner, L.B. & Beal, S.L. (1984) Estimation of altered kinetics in populations. In Pharmacokinetics Basis for Drug Treatment. Ed. Benet, L.Z., Massoud, N. & Gambertoglio, J.G. Raven Press, New York.
57. Sheiner, L.B., Beal, S.L., Rosenberg, B. & Marathe, V.V. (1979) Forecasting individual pharmacokinetics. Clinical Pharmacology and Therapeutics, 26, 294-305.
58. Sheiner, L.B., Rosenberg, B. & Marathe, V.V. (1977) Estimation of population characteristics of pharmacokinetic parameters form routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics, 5, 445-479.
59. Steimer, J.L., Ebelin, M.E. & Van Bree, J. (1993) Pharmacokinetic and pharmacodynamic data and models in clinical trials. European Journal of Drug Metabolism and Pharmacokinetics, 18, 61-76.
60. Steimer, J.L., Mallet, A., Golmard, J. & Boisieux. (1984) Alternative approaches to estimation of population pharmacokinetic parameters: comparison with nonlinear mixed effect model. Drug Metabolism Reviews, 15, 265-292.
61. Thomson, A.H. & Whiting, B. (1992) Bayesian parameter estimation and population pharmacokinetics. Clinical Pharmacokinetics, 22, 447-467.
62. Van Peer, A., Snoeck, E., Huang, M.L. & Heykants, J. (1993) Pharmacokinetic-Pharmacodynamic relationships in Phase I/Phase II of drug development. European Journal of Drug Metabolism and Pharmacokinetics, 18, 49-59.
63. Vozeh, S., Maitre, P.O. & Stanski, D.R. (1990) Evaluation of population (NONMEM) pharmacokinetics parameter estimates. Journal of Pharmacokinetics and Biopharmaceutics, 18, 161-173.
64. Vozeh, S., Steimer, J.L., Rowland, M., Morselli, P., Mentré, F., Balant, L.P. & Aarons, L. (1996) The use of population pharmacokinetics in drug development. Clinical Pharmacokinetics, 30, 81-93.